Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $1,517,880.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the completion of the transaction, the director owned 360,682 shares of the company’s stock, valued at approximately $91,245,332.36. This represents a 1.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $256.56 on Friday. The firm has a market capitalization of $16.66 billion, a PE ratio of 17.69, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 12-month low of $109.87 and a 12-month high of $265.05. The firm has a 50-day moving average price of $241.29 and a 200 day moving average price of $209.52.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same period in the previous year, the firm posted ($8.25) earnings per share. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 21.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. USA Financial Formulas bought a new position in Jazz Pharmaceuticals during the first quarter worth about $25,000. LRI Investments LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $38,000. Danske Bank A S bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at about $40,000. Geneos Wealth Management Inc. raised its position in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on JAZZ. Bank of America raised their price target on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Robert W. Baird increased their target price on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday. UBS Group restated a “buy” rating and issued a $315.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday. Morgan Stanley raised their target price on Jazz Pharmaceuticals from $245.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Royal Bank Of Canada lifted their price target on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $272.74.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz’s quarterly revenue reached $1.21 billion, beating consensus expectations of $1.11 billion and increasing 15.5% year over year. Management also raised its 2026 revenue outlook to $4.60 billion-$4.75 billion, supported by its neuroscience and oncology businesses. What Does Jazz Pharmaceuticals Raised Guidance Mean
• Positive Sentiment: The company’s oxybate franchise, including Xywav, continues to post double-digit growth despite generic Xyrem competition, helping support confidence in the upgraded outlook.
• Positive Sentiment: Analyst sentiment has strengthened. Wells Fargo raised its price target to $300 and maintained an overweight rating, while Morgan Stanley lifted its target to $280. Other firms, including JPMorgan, Needham and Bank of America, also maintain bullish ratings or targets above the recent trading range. Wells Fargo Gives Jazz Pharmaceuticals a Buy
• Positive Sentiment: Ziihera, or zanidatamab, remains a potential catalyst, with an FDA decision expected August 25 for first-line gastroesophageal adenocarcinoma. Approval could expand Jazz’s oncology revenue base.
• Positive Sentiment: Recent coverage describes JAZZ as a strong long-term momentum and value candidate, reflecting its improving earnings outlook and stock performance near its 52-week high. Why Jazz Pharmaceuticals Is a Top Momentum Stock
• Neutral Sentiment: Adjusted earnings per share were $5.71, below the $6.18 consensus estimate. The revenue beat and higher guidance offset the earnings miss, but margins and future profitability remain important risks.
• Negative Sentiment: Jazz plans to seek FDA withdrawal of the second-line lurbinectedin, marketed as Zepzelca, indication for small-cell lung cancer. The move removes a potential regulatory catalyst and underscores pressure on the product’s development prospects. Jazz Seeks FDA Withdrawal of Lurbinectedin Indication
• Negative Sentiment: Director Bruce Cozadd sold 6,000 shares for approximately $1.52 million. The transaction occurred under a pre-arranged Rule 10b5-1 plan and reduced his position by only 1.64%, making it a limited negative signal. Jazz Pharmaceuticals Director Share Sale

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.